Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label Phase Ⅰ/Ⅱ Study of EZH2 Inhibitor SHR2554 in Combination With Anti-PD-L1/TGFβ Antibody SHR1701 in Patients With Advanced or Metastatic Solid Tumors and Relapsed/Refractory B-cell Lymphomas

Next Previous
Trial Profile

An Open-Label Phase Ⅰ/Ⅱ Study of EZH2 Inhibitor SHR2554 in Combination With Anti-PD-L1/TGFβ Antibody SHR1701 in Patients With Advanced or Metastatic Solid Tumors and Relapsed/Refractory B-cell Lymphomas

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 15 Dec 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Retlirafusp alfa (Primary) ; SHR-2554 (Primary)
  • Indications Adenocarcinoma; Advanced breast cancer; B-cell lymphoma; Cholangiocarcinoma; Gastrointestinal cancer; Hodgkin's disease; Lymphoma; Non-small cell lung cancer; Pancreatic cancer; Renal cell carcinoma; Solid tumours; Squamous cell cancer; Triple negative breast cancer
  • Focus Therapeutic Use

Most Recent Events

  • 11 Dec 2023 Planned End Date changed from 1 Dec 2023 to 1 Dec 2025.
  • 11 Dec 2023 Planned primary completion date changed from 1 Mar 2023 to 1 Dec 2024.
  • 06 Jun 2023 Results (By January 6, 2023, n=33 ) assessing safety of SHR-1701 plus SHR2554 in pts with pretreated advanced lymphoma and solid tumors presented at the 59th Annual Meeting of the American Society of Clinical Oncology

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top